Cover Image
市場調查報告書

(5EU)的醫藥品市場預測與分析過敏性鼻炎:歐洲主要5個國家

Allergic Rhinitis - 5EU Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 371769
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
Back to Top
(5EU)的醫藥品市場預測與分析過敏性鼻炎:歐洲主要5個國家 Allergic Rhinitis - 5EU Drug Forecast and Market Analysis to 2024
出版日期: 2015年09月01日 內容資訊: 英文 187 Pages
簡介

本報告提供歐洲主要5個國家 (法國·德國·義大利·西班牙·英國) 的過敏性鼻炎 (AR) 治療藥臨床實驗趨勢與上市預測相關分析,提供您AR概要和症狀·原因,現階段主要治療方法,目前臨床實驗中的開發中產品概要 (功效,SWOT分析及其它),市場規模預測 (今後11年份),主要的推動市場要素與其影響度等調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 疾病概要

  • 病因與病情
  • 分類
    • 季節性·持續性過敏性鼻炎
    • 過敏性鼻炎的ARIA分類
  • 預後
  • 生活品質 (QoL)

第4章 疾病管理

  • 診斷·治療方法概要
    • 診斷
    • 治療指南主要的處方藥
    • 臨床評估
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭產品的評估

  • 概要
  • 口服H1抗組織胺藥物
    • 概要
    • 功效
    • 安全性
    • SWOT分析
    • 未來預測
  • 經鼻抗組織胺藥物
  • 經鼻皮質類固醇
  • 經鼻皮質類固醇/抗組織胺藥物的混合劑 (Dymista)
  • 充血消除藥
  • 經鼻抗膽鹼藥
  • 白三烯素受體拮抗劑
  • Cromones
  • 凝血脂素A2受體拮抗劑
  • TH2細胞激素抑制劑

第6章 未滿足需求與市場機會

第7章 開發中產品的評估

  • 臨床實驗階段有潛力的醫藥品
    • S-555739
    • HP-3060

第8章 市場未來展望

  • (5EU)歐洲主要5個國家
    • 預測
    • 近幾年主要的事件
    • 市場促進·阻礙因素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC319CFR

AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024.

In 2014, the base-year of the forecast period, sales of AR products in the 5EU totaled $2.53 billion. The 5EU AR market will remain stagnant, with no major events occurring over the 10-year forecast period. There are no pipeline AR products set to launch in the 5EU during this time. The patent expiries of the best-selling prescription INCS, Nasonex and Nasacort, will be the events that have the most negative impact on the 5EU AR market during the forecast period.

Scope

  • Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU Allergic Rhinitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
  • 3.2. Symptoms
  • 3.3. Classification
    • 3.3.1. Seasonal and Perennial AR
    • 3.3.2. ARIA Classification of AR
  • 3.4. Diagnosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. France
  • 4.3. Germany
  • 4.4. Italy
  • 4.5. Spain
  • 4.6. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Oral H1 Antihistamines
    • 5.2.1. Overview
    • 5.2.2. Efficacy
    • 5.2.3. Safety
    • 5.2.4. SWOT Analysis
    • 5.2.5. Forecast
  • 5.3. Intranasal Antihistamines
  • 5.4. Intranasal Corticosteroids
    • 5.4.1. Overview
    • 5.4.2. Efficacy
    • 5.4.3. Safety
    • 5.4.4. SWOT Analysis
    • 5.4.5. Forecast
  • 5.5. Combination Intranasal Corticosteroids/Antihistamines
    • 5.5.1. Dymista
  • 5.6. Decongestants
    • 5.6.1. Overview
  • 5.7. Intranasal Anticholinergics
    • 5.7.1. Overview
  • 5.8. Leukotriene Receptor Antagonists
    • 5.8.1. Overview
  • 5.9. Cromones
    • 5.9.1. Overview
  • 5.10. Thromboxane A2 Receptor Antagonists
    • 5.10.1. Overview
  • 5.11. TH2. Cytokine Inhibitors
    • 5.11.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Pharmacist Education
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Patient Compliance With Intranasal Corticosteroids and Antihistamines
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. More Convenient and More Patient-Friendly Immunotherapies
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Primary Care Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Promising Drugs in Clinical Development
    • 7.1.1. S-555739
    • 7.1.2. HP-3060

8. Market Outlook

  • 8.1. 5EU
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Pediatric Allergic Rhinitis Population
    • 9.4.2. Diagnosed AR Patients
    • 9.4.3. Percentage of Drug-Treated Patients
    • 9.4.4. Drugs Included in Each Therapeutic Class
    • 9.4.5. Launch and Patent Expiry Dates
    • 9.4.6. 1General Pricing Assumptions
    • 9.4.7. Individual Drug Assumptions
    • 9.4.8. Generic Erosion
    • 9.4.9. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Director
    • 9.6.3. Epidemiologist
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Airborne Allergens That Cause AR
  • Table 2: Common Symptoms of AR
  • Table 3: Treatment Guidelines for AR
  • Table 4: Most Commonly Prescribed Drugs for AR in the 7MM by Class, 2014
  • Table 5: Major Brands of INCS
  • Table 6: Management of AR, Country Profile - France
  • Table 7: Management of AR, Country Profile - Germany
  • Table 8: Management of AR, Country Profile - Italy
  • Table 9: Management of AR Country Profile - Spain
  • Table 10: Management of AR Country Profile - UK
  • Table 11: Effects of Main Drug Classes on AR Symptoms
  • Table 12: Leading Branded Drugs Used to Treat AR, 2014
  • Table 13: Major Brands of Second- and Third-Generation Non-Sedating AHs
  • Table 14: Product Profile - AHs
  • Table 15: Efficacy of Bilastine in Symptomatic SAR Patients Age 12-70 Years
  • Table 16: Safety of Bilastine in Symptomatic SAR Patients Age 12-70 Years
  • Table 17: Oral AHs SWOT Analysis, 2014
  • Table 18: Global Sales Forecasts ($m) for Oral AHs, 2014-2024
  • Table 19: Major Brands of Intranasal Ahs
  • Table 20: Major Brands of INCS
  • Table 21: Product Profile - INCS
  • Table 22: Efficacy of FP ANS and BDP ANS in AR Patients Age 18-72 Years
  • Table 23: Safety Profile of FP ANS and BDP ANS in AR Patients Age 18-72 Years
  • Table 24: INCS SWOT Analysis, 2014
  • Table 25: Global Sales Forecasts ($m) for INCS, 2014-2024
  • Table 26: Product Profile - Dymista
  • Table 27: Efficacy of Dymista
  • Table 28: Safety of Dymista
  • Table 29: Dymista SWOT Analysis, 2014
  • Table 30: Global Sales Forecasts ($m) for Dymista, 2014-2024
  • Table 31: Unmet Need and Opportunity in AR
  • Table 32: Late-Stage Pipeline for AR, 2014
  • Table 33: Product Profile - S-555739
  • Table 34: Completed Clinical Trials of S-555739 in AR Patients
  • Table 35: S-555739 SWOT Analysis, 2014
  • Table 36: Global Sales Forecasts ($) for S-555739, 2014-2024
  • Table 37: Product Profile - HP-3060
  • Table 38: HP-3060 SWOT Analysis, 2014
  • Table 39: Global Sales Forecasts ($) for HP-3060, 2014-2024
  • Table 40: Sales Forecasts ($m) for AR in the 5EU, 2014-2024
  • Table 41: Key Events Impacting Sales for AR in the 5EU, 2014-2024
  • Table 42: AR Market - Drivers and Barriers in the 5EU, 2014
  • Table 43: Abbreviations
  • Table 44: Key Launch Dates of the Currently Available AR Therapies
  • Table 45: Key Loss of Exclusivity Dates of the Currently Available AR Therapies
  • Table 46: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Immunological Mechanisms Involved in the Early- and Late-Phase Allergic Response
  • Figure 2: ARIA Classification of AR by Duration of Symptoms and Severity
  • Figure 3: Algorithm Used for the Management of AR in the 7MM*
  • Figure 4: Sales for AR in the 5EU by Drug Class, 2014-2024
Back to Top